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Abstract. In a 2009 Cochrane review, the authors concluded that there is good evidence that statins, given in late life to people at
risk of vascular disease, have no effect in preventing Alzheimer’s disease or dementia. A related issue, which remains unclear, is
whether statins improve cognitive function. While some studies have shown a beneficial effect of statins on cognitive function,
others have observed mild detrimental effects on cognition. Our aim was to assess cognitive function in community-dwelling
elderly participants treated with statins compared with their untreated counterparts (i.e., controls) living in the same population.
137 population-dwelling participants who were receiving statins and 411 matched controls age ! 65 years (median = 72 years)
in central Spain (the Neurological Disorders in Central Spain [NEDICES] study) underwent a neuropsychological assessment,
including tests of global cognitive performance, frontal-executive function, verbal fluency, and memory. Median duration of
statin treatment was 2 years. Of 137 participants receiving statins, 53 (38.7%) were taking pravastatin, 38 (27.7%) simvastatin,
37 (27.0%) lovastatin, 6 (4.4%) fluvastatin, and 3 (2.2%) atorvastatin. Although initial univariate analyses indicated some
differences, after adjusting for age, gender, education, depressive symptoms, premorbid intelligence, medications that potentially
affect cognitive function, and blood cholesterol levels, statin users and controls performed similarly on all neuropsychological
tests. In this population-based sample, elderly participants treated with statins and untreated controls performed similarly in all
tested cognitive areas. These results do not support a positive benefit of statins on cognition.
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INTRODUCTION
The identification of modifiable risk factors for
neurodegenerative diseases has important implica-
tions in terms of slowing or halting the progression
of those diseases. Recent interest in 3-hydroxy-3-
methylglutaryl coenzymeA (HMG-CoA) reductase in-
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hibitors (“statins”) has been sparked by the notion
that these medications, which act via a cholesterol-
dependent mechanism, might reduce the production
of amyloid-β peptide, the major constituent of senile
plaques, and, hence, the risk of developingAlzheimer’s
disease (AD) [1]. Indeed, a growing literature, with
mixed results, has examined whether the use of these
medications might lower the odds or risk of AD [2–4].
However, in a 2009 Cochrane review, the authors con-
cluded that there is good evidence that statins given in
late life to people at risk of vascular disease have no
effect in preventing AD or dementia [5].
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Arelated issue that remains unclear iswhether statins
might improve or affect cognitive function. On the one
hand, statins were found to have beneficial effects on
cognition in the non-demented elderly in three clini-
cal trials [6–8] and in three community or population-
based surveys [9–11]. On the other hand, one random-
ized clinical trial has showed that statins may cause
detrimental effects on cognitive performance in hyper-
cholesterolemic adults aged 35–70 years [12]. In ad-
dition, cognitive function was unaffected in the elderly
in two placebo-controlled trials of statin treatment [13,
14]. In all but three of these previous studies, partic-
ipants were ascertained through clinical trials [9–11].
Therefore, selection factors may have influenced the
findings of the clinical trials [6–8]. In addition, unmea-
sured confounders, including medications that poten-
tially affect cognitive function (e.g., anxiolytics, stim-
ulants, antipsychotics, antidepressants, antihistamines,
or antiepileptics drugs) [15] may have influenced the
results of previous clinical trials [6,8,12,13] and com-
munity or population-based surveys outcomes [9–11].
We conducteda cross-sectional study of cognitive func-
tion in people treated with statins in a population-based
elderly Spanish cohort. Our goal was to determine
whether population-dwelling elderly individuals who
were receiving statins have cognitive deficits or a better
cognitive performancewhen comparedwith their coun-
terparts living in the same population and not receiving
statins. Our analyses adjusted for several confounders,
including premorbid intelligence and medications with
central nervous system effects [15].
METHODS
Study population
Data for these analyses were derived from the
Neurological Disorders in Central Spain (NEDICES)
study, a longitudinal, population-based survey of the
prevalence, incidence, and determinants of major age-
associated conditions of the elderly, including Parkin-
son’s disease, essential tremor, stroke, and demen-
tia [16–25]. Detailed accounts of the study population
and sampling methods have been published [23–25].
The study population was composed of elderly sub-
jects, ! 65 years old, living in three communities in
central Spain (LasMargaritas, Lista, andAre´valo). The
registered study population was 6,395, but 481 people
were ineligible (census issues, address errors, or death),
leaving 5,914 eligible subjects, of whom 5,278 were
enrolled. All procedures were approved by the ethical
standards committees on human experimentation at the
UniversityHospitals “12 deOctubre” (Madrid) and “La
Princesa” (Madrid). Written (signed) informed consent
was obtained from all participants upon enrollment.
Study evaluation
Detailed accounts of the study assessments have been
published [23–25]. Face-to-face evaluations were per-
formed at baseline (1994–1995) and then at follow-up
(1997–1998). During the face-to-face evaluation, data
were collected on demographics, current medications
including statins and medications with central nervous
system effects [15], medical conditions (e.g., diabetes
mellitus, hypertension, heart disease), and the presence
of depressive symptoms (the question, do you suffer
from depression?). A short form of the questionnaire
wasmailed to subjectswho refused,orwere unavailable
for face-to-face or telephone screening. This form as-
sessed demographic characteristics, several neurolog-
ical disorders (essential tremor, stroke, dementia, and
parkinsonism), current medications, and the name of
their family doctor. During the second (i.e., follow-up)
evaluation (1997–1998), the same methods were used.
The data used in this study are from the second eval-
uation, which was carried out between 1997 and 1998,
and included a neuropsychological test battery, which
was implemented by psychologists, social workers, stu-
dent nurses, and general physicians, all of whom had
been trained by a senior clinical investigatorwith exper-
tise in health sciences research (see acknowledgements,
J.R-N.). In addition, in this second evaluation, blood
samples for cholesterol determinations were drawn.
In the second evaluation, we identified all partici-
pants whowere then being treatedwith statins onwhom
complete neuropsychological test data and cholesterol
blood levels were available (N = 137). These partic-
ipants were 1:3 frequency-matched with control sub-
jects who were not receiving statins at the time of
the second evaluation and who had complete neu-
ropsychological test data and cholesterol blood levels.
Frequency-matching was based on age (five year age
categories), gender, educational category (none, can
read and write, primary school, secondary school, and
higher education), and intake of medications with cen-
tral nervous system effects [15].
Neuropsychological battery
Many tools have been recommended for screening
cognitive deficits in the elderly. Performance on these
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Fig. 1. Flow chart of the study.
tests can be influenced by age, educational level, eth-
nicity, and functional limitations [26,27]. Most screen-
ing tools have been developed in countries where sec-
ondary education is common. When used in popula-
tions with lower levels of education, there may be a
high proportionof false positives [26,27]. In the second
evaluation of the NEDICES study, 54.4% of the 3,816
screened subjects (Fig. 1) were either illiterate or could
only read andwrite. We designed a neuropsychological
battery that was more appropriate for our cohort; it was
similar to that used in the “Aging in Legane´s” study,
a population-based survey carried out in Legan e´s city
(central Spain) [26,27]. Our selection of tests was also
influenced by their ease of use in an epidemiological
setting. Neuropsychological tests were as follows:
Global cognitive performance
An expanded, 37-item version of the Mini-Mental
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State Examination (MMSE) was administered [28,
29]. More specifically, the 37-MMSE was adopted
to Chilean, Maltese, and Spanish socio-cultural back-
grounds and then validated against clinical diagnoses
of dementia [21,22,30–33]. The 37-MMSE included
all of the standard MMSE [30] items as well as three
additional items: 1) an attention task, i.e., say 1, 3, 5,
7, 9 backwards; 2) a visual order, i.e., a man raising his
arms; and 3) a simple construction task, i.e., copying
two overlapping circles [21,22,30–33].
Frontal executive function
The easier form A of the Trail Making Test [34] was
used. The subject linked, in successive order, the num-
bers 1 to 25, which were randomly distributed on a
sheet of paper. Scoring was based on the time required
to complete the task (> 5min versus" 5min) and num-
ber of errors (higher scores indicate greater cognitive
impairment) [34].
Verbal fluency
Subjects were asked to name as many different an-
imals and fruits as they could in 60 seconds (lower
scores indicate greater cognitive impairment) [35].
Memory
The six objects test was used [26,27], which con-
sisted of the naming test that tested the ability to name
line drawings of six common objects (range 0 [greater
cognitive impairment] to 6); immediate free recall of
the six objects (range 0 [greater cognitive impairment]
to 6); and delayed free recall of the six objects 5 min
later (range 0 [greater cognitive impairment] to 6). Al-
so used was the story recall task [36], which required
participants to listen to a brief narrative containing six
informational bits. Their recall immediately after hear-
ing the story (immediate logical memory) and after a
20-min delay (delayed logical memory) were assessed
(range 0 [greater cognitive impairment] to 6) [36].
Premorbid intelligence
This was evaluatedwith theWordAccentuationTest,
which assessed the ability to accentuate 30 infrequently
used Spanish words (range 0 [greater impairment] to
30) [37].
Statistical analyses
Analyses were performed in SPSS (version 15.0).
Demographic and clinical characteristics of cases and
controls were compared using Student’s t tests and
chi square tests. None of the neuropsychological
tests scores was normally distributed (Kolmogorov-
Smirnov, p < 0.001), even after log-transformation.
Therefore, scores were compared using a non-parame-
tric approach (Mann-Whitney test andSpearman’s rho).
Linear regression analyses were not possible because
the neuropsychological tests scores were not normal-
ly distributed. Therefore, to assess the effects of pos-
sible confounders (age, gender, education, depressive
symptoms, and medications that potentially affect cog-
nitive function), we divided the neuropsychological
tests scores into two strata (highest quartile scores vs.
all other scores). Logistic regression analyses were
then performed, thereby allowing us to assess the pos-
sible confounding effects of age, gender, education,
depressive symptoms, premorbid intelligence, medi-
cations that potentially affect cognitive function, and
blood cholesterol levels. In these models, the depen-
dent variable was the highest quartile of each one of the
neuropsychological tests scores (reference = all other
scores) and the independent variable was statin use vs.
non-use. These analyses generated odds ratios (OR)
with 95% confidence intervals (CI).
RESULTS
Of the 5,278 participants screened at baseline, 672
were lost to follow-up either because they declined
(n = 112) or were unreachable (n = 560), and 790 died
before they were contacted the second time (Fig. 1).
Of the remaining 3,816, there were 173 participants
who were taking statins and 3,643 who were not. We
excluded 836 participants because they had incomplete
neuropsychological assessments and 784 because of
absence of data on blood cholesterol levels. Therefore,
the eligible sample for the study consisted of 2,196
subjects (Fig. 1).
The group of 1,620 subjects who were not included
in the study because they had an incomplete neuropsy-
chological assessments or absence of data on blood
cholesterol levels were older than those who were el-
igible for the study (mean = 76.4 ± 6.7 vs. 75.7 ±
6.1 years, Student’s t-test, t = 3,261, p = 0.001), less
educated (χ2(1) = 119.1, p < 0.001) and a larger pro-
portion were women (60.1% versus 57.3%, χ2 = 2.96,
p = 0.09). The excluded and eligible participants al-
so differed with respect to the proportion who were
statin users (36 [2.2% vs. 137 [6.2%], χ2 = 34.75, p <
0.001).
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Table 1
Demographic and Clinical Characteristics of Participants Receiving Statins and Controls
On statins (N = 137) Controls (N = 411) Significance
Age (years) 73.4± 4.4 73.3 ± 5.1 0.83a
Gender (female) 85 (62.0) 243 (59.1) 0.61b
Educational level 0.41b
None 7 (5.1%) 32 (8.3%)
Can read and write 59 (43.1%) 149 (36.3%)
Primary school 48 (35.0%) 156 (38.0%)
Secondary school or higher 23 (16.8%) 72 (17.5%)
On medication with CNS effects 31 (22.6) 91 (22.1) 0.91b
Diabetes mellitus∗ 26 (19.0) 59 (14.4) 0.22b
Hypertension 85 (62.0) 208 (50.6) 0.02b
Heart disease 28 (20.4) 34 (8.3) < 0.001b
Dementia 2 (1.5%) 9 (2.2%) 0.74b
Stroke 8 (5.8%) 22 (5.4%) 0.83b
Current smoker 12 (8.9%) 51 (12.6%) 0.28b
Current drinker 48 (35.6%) 147 (36.6%) 0.92b
Subjective memory complaints∗ 57 (42.9) 171 (43.1) 1.0b
Depressive symptoms 33 (24.1) 79 (19.2) 0.22b
Body mass index (kg/m2)∗ 28.1± 4.7 27.8 ± 4.4 0.52a
Serum cholesterol levels (mmol/L) 4.4 ± 0.9 4.3± 0.7 0.15a
aStudent’s t test; bChi-square test; ∗Data on some participants were missing.
Mean ± standard deviation and frequency (%) are reported.
The 137 participants receiving statins and 411
frequency-matched controls were similar in most re-
spects, with the exception of the prevalence of hyper-
tension and heart diseases (Table 1). Median dura-
tion of statin treatment was 2 years. Of the 137 peo-
ple receiving statins, 53 (38.7%) were taking pravas-
tatin, 38 (27.7%) simvastatin, 37 (27.0%) lovastatin,
6 (4.4%) fluvastatin, and 3 (2.2%) atorvastatin. The
median statin dose was of 20 mg (range 10 to 40 mg).
In our controls, we examined whether neuropsycho-
logical test scores (esp. 37-MMSE) were associated
with potential confounding variables. The 37-MMSE
was correlated with age (rS = −0.297, p < 0.001),
gender (mean ± SD [median] = 31.3 ± 5.5 [33] in
men vs. 29.5 ± 4.8 [30] in women, Mann-Whitney
U test, p = 0.001), educational category (rS = 0.33,
p < 0.001), subjective depressive symptoms (28.3 ±
4.9 [29] in those who responded “yes” vs. 30.7 ±
5.1 [32] in those who responded “no”, Mann-Whitney
U test, p < 0.001). The 37-MMSE was marginally
correlated with medications that could affect cognition
(mean± SD [median]= 29.4± 5.3 [30] in those taking
a medication vs. 30.4 ± 5.0 [31] in those who do not
take a medication, Mann-Whitney U test, p = 0.12).
Statin users versus non-users differed with respect to
verbal fluency tests, naming, immediate free recall, and
premorbid intelligence; performance on the 37-MMSE
was marginally different (p = 0.062) with the controls
performing more poorly (Table 2). However, in a re-
gression analysis that adjusted for age in years, gender,
educational category, premorbid intelligence, intake of
any medication that can affect cognition (one variable
coded as yes vs. no), depressive symptoms (coded as
yes vs. no), and blood cholesterol levels, we found that
exposure category (statin use vs. control) was associ-
ated with none of the highest quartiles of neuropsycho-
logical tests scores (Table 3). In participants receiving
statins, treatment duration was not correlated with any
neuropsychological test score results (data not shown).
DISCUSSION
We examined a population-dwelling sample of older
people in central Spain who were taking statins. After
adjusting for potential confounders, including medica-
tions with central nervous effects and premorbid intel-
ligence, participants taking statins did not differ from
their untreated counterparts in the performance of for-
mal neuropsychological tests. Our results are in line
with two placebo-controlled trials of statin treatment
in the elderly [13,14]. Antidepressants, anxiolytics,
stimulants, antihypertensives, antiepileptics, or antihis-
tamines can affect psychomotor functioning, concen-
tration, and memory [15]. Hence, it is important to ad-
just for the use of these types of medications when as-
sessing cognition using a neuropsychological test bat-
tery [15]. We also adjusted for serum total cholesterol
level, since there is evidence that cholesterol may af-
fect cognition; higher midlife serum total cholesterol
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Table 2
Neuropsychological Tests Performance of Participants Receiving Statins and Controls
Cognitive domain Neuropsychological tests People receiving statins Controls p value
Global Cognitive Performance 37-MMSE (range = 0–37) 31.0 ± 5.2 (33) 30.2 ± 5.1 (31) 0.062a
Frontal Executive Function Trail making test-A (number of errors) 1.2 ± 3.8 (0) 1.7 ± 7.6 (0) 0.140a
Trail making test-A (time to complete it) > 5 minutes 14 (11.3%) 34 (9.5%) 0.602b
Verbal Fluency Verbal fluency (animals) 14.8 ± 5.0 (15) 13.4 ± 4.7 (13) 0.002a
Verbal fluency (fruits) 11.4 ± 3.4 (11) 10.6 ± 3.4 (10) 0.014a
Memory Naming test (score 0–6) 5.9 ± 0.5 (6) 5.7 ± 0.8 (6) 0.040a
Immediate free recall (score 0–6) 4.6 ± 1.1 (5) 4.3 ± 1.2 (4) 0.013a
Delayed free recall (score 0–6) 4.3 ± 1.5 (5) 4.1 ± 1.6 (4) 0.338a
Immediate logical memory (score 0-6) 3.9 ± 1.7 (5) 4.4 ± 1.5 (5) 0.149a
Delayed logical memory (score 0–6) 4.1 ± 2.0 (5) 3.7 ± 2.1 (4) 0.050a
Premorbid Intelligence Word Accentuation Test (score 0–30) 18.5 ± 9.1 (20) 16.4 ± 8.7 (16) 0.030a
Results are means ± standard deviations and (medians). MMSE=Mini-Mental State Examination.aMann-Whitney U test. bChi-square.
Table 3
Highest Quartile of Each One of the Neuropsychological Tests Scores and Odds of Being Treated with Statins
Neuropsychological tests Unadjusted Adjusted∗∗
Odds ratio 95% CI p value Odds ratio 95% CI p value
highest quartile of 37-MMSE 1.0 0.7–1.6 0.82 1.1 0.6–2.0 0.66
Highest quartile of Trail making test-A (errors) 0.8 0.5–1.4 0.47 0.8 0.4-1.4 0.40
Trail making test-A (time to complete it)∗ 1.2 0.6–2.3 0.57 1.7 0.8–3.8 0.17
Highest quartile of verbal fluency (animals) 1.8 1.1–2.7 0.008 1.7 0.9–2.9 0.06
Highest quartile of verbal fluency (fruits) 1.6 1.1–2.5 0.02 1.3 0.8–2.3 0.31
Highest quartile of naming test 2.0 1.0–4.1 0.045 1.5 0.6–3.4 0.37
Highest quartile of immediate free recall 1.3 0.8–2.1 0.27 1.4 0.8–2.6 0.21
Highest quartile of delayed free recall 0.9 0.5–1.5 0.73 1.0 0.5–2.0 0.90
Highest quartile of immediate logical memory 1.2 0.8–1.8 0.40 1.2 0.7–2.0 0.45
Highest quartile of delayed logical memory 1.3 0.8–2.0 0.23 1.1 0.7–1.9 0.61
∗In this model, the dependent variable was > 5 minutes to complete the Trail Making Test (reference < 5 minutes).
∗∗Adjusted for age, gender, educational category (none, can read and write, primary school, secondary school and higher
education), premorbid intelligence, intake of medications that potentially affect cognition function, depressive symptoms, and
blood cholesterol levels.
may be associated with poorer late-life cognition, but
decreasing serum total cholesterol after midlife may
reflect poorer cognitive status [11]. Furthermore, in
oldest old (! 85 years) nondemented noncarriers of the
APOE4 allele, high cholesterol may be associated with
better memory function [38].
Better performance on neuropsychological tests has
been observed in prior clinical trials and communi-
ty or population-based surveys. In the Heart and Es-
trogen/progestin Replacement Study of 1,037 post-
menopausal women < 80 years with coronary heart
disease the Modified MMSE (scores ranging from 0
to 100) was administered after 4 years of follow-up.
Compared with nonusers, statin users had higher mean
± standard deviationsModifiedMMSE scores (vs. 93.7
± 6.1 vs. 92.7 ± 7.1, p = 0.02) [6]. Furthermore, in
a case-control study, 55 people age 40 or older treat-
ed with atorvastatin scored significantly better than the
placebo group in several cognitive areas, including at-
tention, psychomotor speed, mental flexibility, work-
ing memory, and memory retrieval [7]. In line with
this, in another study, improvement in verbal fluen-
cy and working memory were observed in the sim-
vastatin treated group (29 asymptomatic middle-aged
adult children of people with AD) compared to 28 con-
trols [8]. In a prospective community-based study of
3,334 people age 65 or older study, the rate of decline
on the Modified MMSE was 0.48 point/year less in
those taking statins compared with the untreated group
for whom treatment was recommended (p = 0.069)
and 0.49 point/year less in statin users compared with
the group in whom lipid-lowering treatment was not
recommended (p = 0.009) [9]. In addition, a recent
prospective community-based study of 1,146 African
Americans aged 70 and older living in Indianapolis,
Indiana, showed that baseline statin use was associated
with less dementia (OR= 0.32; p = 0.07) and less cog-
nitive decline (p = 0.02) [10]. Finally, a longitudinal
population-based study of 1,382middle-aged adults re-
examined after an average follow-up of 21 years also
suggested that statins might be beneficial for cognition
in nondemented elderly [11]. In contrast, statins use
has been associated with more cognitive impairment.
Thus, in a randomized trial comprising 308 hyperc-
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holesterolemic adults between 35 and 70 years of age,
minor decrements in cognitive function were observed
with statins [12]. Themechanism bywhich statins may
affect cognitive function is not known. The authors ar-
gued that there are several possibilities, including that
statins might alter neuronal function through effects
on brain cholesterol metabolism, ubiquinone, protein
prenylation, vitamin E, and omega-3 fatty acids [12].
Our study has limitations. First, the cross-sectional
sample does not allow us to examine causation. Sec-
ond, we only included people aged 65 and older; the
NEDICES study, in which this study was nested, was a
study of the elderly (age 65 years and older). However,
the study of the relationship statins-cognition in elderly
people is of special interest, since prevalence and inci-
dence of cognitive problems is higher in this age group
anyway [21,22]. Third, we used a relatively restrict-
ed neuropsychological test battery that did not sample
all cognitive domains. Our battery was designed to
meet the constraints of an epidemiological study in a
cohort with lower levels of education and our selec-
tion of tests was also influenced by their ease of use
in a population sample of approximately 4,000 elder-
ly subjects in an epidemiological setting [26,27]. Fi-
nally, we assessed depressive symptoms by self-report
and, although our screening question was modeled on a
question that correctly diagnosed depression in 85.4%
of participants [39], we may have under-ascertained
depression. However, based on a validation study in
which we showed a high level of agreement between
the data generated from this screening question and a
more detailed in-person psychiatric assessment [40],
we think that such misclassification errors were likely
to be low.
This study also has several strengths. We attempted
to adjust for the effects of many potential confounders.
Finally, the study was population-based, allowing us
to assess a group of people unselected (unlike clinical
trials) for treatment with statins.
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